Pharmacoeconomics of COPD and smoking cessation

Comment

F W Grannis Jr. Chest. 2001 Jul.

. 2001 Jul;120(1):321.

doi: 10.1378/chest.120.1.321.

No abstract available

Comment on

Pharmacoeconomic evaluation of COPD.
Hilleman DE, Dewan N, Malesker M, Friedman M. Hilleman DE, et al. Chest. 2000 Nov;118(5):1278-85. doi: 10.1378/chest.118.5.1278. Chest. 2000. PMID: 11083675

The health care costs of smoking.
Hodgson TA. Hodgson TA. N Engl J Med. 1998 Feb 12;338(7):470; author reply 472. doi: 10.1056/NEJM199802123380713. N Engl J Med. 1998. PMID: 9463152 No abstract available.
COPD exacerbations.
Haggerty MC. Haggerty MC. Thorax. 2001 Sep;56(9):740. doi: 10.1136/thorax.56.9.740. Thorax. 2001. PMID: 11563358 Free PMC article. No abstract available.
Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
Cedillo S, Sicras-Mainar A, Jiménez-Ruiz CA, Fernández de Bobadilla J, Rejas-Gutiérrez J. Cedillo S, et al. Eur Addict Res. 2017;23(1):7-18. doi: 10.1159/000449098. Epub 2016 Oct 29. Eur Addict Res. 2017. PMID: 27794567
Management of patients with chronic obstructive pulmonary disease in ICU and promotion of smoking cessation.
O'Connell L. O'Connell L. Nurs Crit Care. 2000 May-Jun;5(3):130-6. Nurs Crit Care. 2000. PMID: 11249255 Review.
Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options.
Friedman M, Hilleman DE. Friedman M, et al. Pharmacoeconomics. 2001;19(3):245-54. doi: 10.2165/00019053-200119030-00003. Pharmacoeconomics. 2001. PMID: 11303413 Review.